Ligand Pharmaceuticals Incorporated (LGND) Q3 2017 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Down 1.5%

Ligand Pharmaceuticals reported a strong earnings per share, significantly exceeding expectations. Despite this positive news, the stock fell by 1.5% on the day of the announcement. Investors may be reacting to the lack of revenue details and forward guidance, which could raise concerns about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.69	N/A	+193.96%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the earnings surprise, highlighting ongoing efforts in partnerships. However, they did not provide specific guidance for future quarters.

We are pleased with our earnings performance this quarter.

Our focus remains on strategic partnerships and product development.

Ligand Pharmaceuticals Beats on EPS, Stock Down 1.5%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Down 1.5%

Key numbers

Management commentary